#METABOLOMICS WORKBENCH hjyoo2_20200818_181947 DATATRACK_ID:2131 STUDY_ID:ST001467 ANALYSIS_ID:AN002443 PROJECT_ID:PR000999
VERSION             	1
CREATED_ON             	August 27, 2020, 10:02 am
#PROJECT
PR:PROJECT_TITLE                 	Treatment of chemotherapy-induced cachexia with BST204: a multimodal validation
PR:PROJECT_TITLE                 	study
PR:PROJECT_SUMMARY               	A multimodal approach was performed to investigate the effects of BST204 on the
PR:PROJECT_SUMMARY               	alleviation of chemotherapy-induced cachexia. The targeted metabolome changed
PR:PROJECT_SUMMARY               	with chemotheraphy-induced cachexia and the changes were reversed with potential
PR:PROJECT_SUMMARY               	treatment of the cachexia.
PR:INSTITUTE                     	Asan medical Center, University of Ulsan College of Medicine
PR:LAST_NAME                     	Yoo
PR:FIRST_NAME                    	Hyun Ju
PR:ADDRESS                       	88, Olympic-ro, 43-gil, Songpa-gu, Seoul 05505, South Korea
PR:EMAIL                         	yoohyunju@amc.seoul.kr
PR:PHONE                         	82-02-3010-4029
#STUDY
ST:STUDY_TITLE                   	Metabolites changes related to glucose-mediated energy production in
ST:STUDY_TITLE                   	chemotheraphy-induced cachexia
ST:STUDY_SUMMARY                 	Targeted metabolomics platforms included amino acids and metabolites related to
ST:STUDY_SUMMARY                 	glucose-mediated energy production. The targeted metabolome changed with
ST:STUDY_SUMMARY                 	chemotheraphy-induced cachexia, and the changes were reversed with potential
ST:STUDY_SUMMARY                 	treatment of the cachexia. .rdb files were included as raw data files where
ST:STUDY_SUMMARY                 	detailed information regarding MRM transitions and internal standards can be
ST:STUDY_SUMMARY                 	found. Several amino acids (Gly, Pro, Gln, Taurine) were analyzed after dilution
ST:STUDY_SUMMARY                 	because their peak intensities were too high. Thus their analysis was performed
ST:STUDY_SUMMARY                 	separately from other amino acids, and their rdb files were saved in separate
ST:STUDY_SUMMARY                 	rdb files.
ST:INSTITUTE                     	Asan medical Center, University of Ulsan College of Medicine
ST:LAST_NAME                     	Yoo
ST:FIRST_NAME                    	Hyun Ju
ST:ADDRESS                       	88, Olympic-ro, 43-gil, Songpa-gu, Seoul 05505, South Korea
ST:EMAIL                         	yoohyunju@amc.seoul.kr
ST:PHONE                         	82-02-3010-4029
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_1p	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_2p	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_3p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_4p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_5p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_6p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	TB	TB_1p	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	TB	TB_2p	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	TB	TB_3p	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	TB	TB_4p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	TB	TB_5p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	TB	TB_6p	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_1p	Group:batch1 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_2p	Group:batch1 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_3p	Group:batch1 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_4p	Group:batch2 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_5p	Group:batch2 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_6p	Group:batch2 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_1p	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_2p	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_3p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_4p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_5p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_6p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_1p	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_2p	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_3p	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_4p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_5p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_6p	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_1m	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=27; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_2m	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_3m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_4m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_5m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_6m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_1m	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_2m	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_3m	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_4m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_5m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_6m	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_1m	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_2m	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_3m	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_4m	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_5m	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=23; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_6m	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_1m	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_2m	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_3m	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_4m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=33; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_5m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_6m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=34; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_1m	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_2m	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=AA_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_3m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_4m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_5m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=24; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_6m	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_1p_2	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_2p_2	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_3p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_4p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_5p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_6p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	TB	TB_1p_2	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	TB	TB_2p_2	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	TB	TB_3p_2	Group:batch1 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	TB	TB_4p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	TB	TB_5p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	TB	TB_6p_2	Group:batch2 | Treatment:Control | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_1p_2	Group:batch1 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_2p_2	Group:batch1 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_3p_2	Group:batch1 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_4p_2	Group:batch2 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_5p_2	Group:batch2 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_6p_2	Group:batch2 | Treatment:5FU | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_1p_2	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_2p_2	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_3p_2	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_4p_2	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_5p_2	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_6p_2	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_1p_2	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_2p_2	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_3p_2	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_4p_2	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_5p_2	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_6p_2	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_1m_2	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=27; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_2m_2	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_3m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_4m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_5m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_6m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_1m_2	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_2m_2	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_3m_2	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_4m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_5m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_6m_2	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_1m_2	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_2m_2	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_3m_2	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_4m_2	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_5m_2	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=23; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_6m_2	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_1m_2	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_2m_2	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_3m_2	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_4m_2	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=33; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_5m_2	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_6m_2	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=34; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_1m_2	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_2m_2	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_3m_2	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Energy metabolism_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_4m_2	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_5m_2	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=24; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_6m_2	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_1m_1	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=27; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_2m_1	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_3m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_4m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_5m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	NTB	NTB_6m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_1m_1	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_2m_1	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_3m_1	Group:batch1 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	TB	TB_4m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_5m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	TB	TB_6m_1	Group:batch2 | Treatment:Control | Sample Source:muscle	Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_1m_1	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_2m_1	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_3m_1	Group:batch1 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_4m_1	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_5m_1	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=23; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	5FU	5FU_6m_1	Group:batch2 | Treatment:5FU | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_1m_1	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_2m_1	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_3m_1	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_4m_1	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=33; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_5m_1	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	BST100	BST100_6m_1	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=34; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_1m_1	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_2m_1	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_3m_1	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_4m_1	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_5m_1	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=24; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
SUBJECT_SAMPLE_FACTORS           	BST200	BST200_6m_1	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2
#COLLECTION
CO:COLLECTION_SUMMARY            	Mice were randomized into five groups (n = 10 each): untreated,
CO:COLLECTION_SUMMARY            	non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group);
CO:COLLECTION_SUMMARY            	tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving
CO:COLLECTION_SUMMARY            	5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving
CO:COLLECTION_SUMMARY            	5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells
CO:COLLECTION_SUMMARY            	(1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of
CO:COLLECTION_SUMMARY            	phosphate-buffered saline were subcutaneously implanted in the right flank of
CO:COLLECTION_SUMMARY            	8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached
CO:COLLECTION_SUMMARY            	100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was
CO:COLLECTION_SUMMARY            	assigned and drug administration started for 5-FU and BST204 groups. BST204
CO:COLLECTION_SUMMARY            	(batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South
CO:COLLECTION_SUMMARY            	Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50
CO:COLLECTION_SUMMARY            	mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2;
CO:COLLECTION_SUMMARY            	2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable.
CO:COLLECTION_SUMMARY            	BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle:
CO:COLLECTION_SUMMARY            	days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according
CO:COLLECTION_SUMMARY            	to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our
CO:COLLECTION_SUMMARY            	study was determined according to IACUC guidelines, which recommend euthanasia
CO:COLLECTION_SUMMARY            	with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our
CO:COLLECTION_SUMMARY            	study period was limited to day 11. At this point, the change in tumor volumes
CO:COLLECTION_SUMMARY            	was up to 810%, and significant cachexia was observed.
CO:SAMPLE_TYPE                   	Blood (plasma)
CO:COLLECTION_LOCATION           	muscle
CO:STORAGE_CONDITIONS            	-20℃
#TREATMENT
TR:TREATMENT_SUMMARY             	Mice were randomized into five groups (n = 10 each): untreated,
TR:TREATMENT_SUMMARY             	non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group);
TR:TREATMENT_SUMMARY             	tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving
TR:TREATMENT_SUMMARY             	5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving
TR:TREATMENT_SUMMARY             	5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells
TR:TREATMENT_SUMMARY             	(1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of
TR:TREATMENT_SUMMARY             	phosphate-buffered saline were subcutaneously implanted in the right flank of
TR:TREATMENT_SUMMARY             	8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached
TR:TREATMENT_SUMMARY             	100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was
TR:TREATMENT_SUMMARY             	assigned and drug administration started for 5-FU and BST204 groups. BST204
TR:TREATMENT_SUMMARY             	(batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South
TR:TREATMENT_SUMMARY             	Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50
TR:TREATMENT_SUMMARY             	mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2;
TR:TREATMENT_SUMMARY             	2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable.
TR:TREATMENT_SUMMARY             	BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle:
TR:TREATMENT_SUMMARY             	days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according
TR:TREATMENT_SUMMARY             	to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our
TR:TREATMENT_SUMMARY             	study was determined according to IACUC guidelines, which recommend euthanasia
TR:TREATMENT_SUMMARY             	with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our
TR:TREATMENT_SUMMARY             	study period was limited to day 11. At this point, the change in tumor volumes
TR:TREATMENT_SUMMARY             	was up to 810%, and significant cachexia was observed.
TR:TREATMENT                     	5-FU was injected intraperitoneally in 3-day cycles. BST204 was orally
TR:TREATMENT                     	administerd in 5-day cycles.
TR:TREATMENT_DOSE                	5-FU (50 mg/kg), BST204 (100 or 200 mg/kg)
TR:ANIMAL_ENDP_EUTHANASIA        	study period was limited by day 11
TR:TREATMENT_COMPOUND            	5-FU, BST204
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Metabolites related to glucose-mediated energy metabolism were extracted using
SP:SAMPLEPREP_SUMMARY            	LLE. Amino acids and bioamines were also extracted using LLE and underwent
SP:SAMPLEPREP_SUMMARY            	chemical derivatization with phenylisothiocyante.
SP:PROCESSING_STORAGE_CONDITIONS 	4℃
SP:EXTRACTION_METHOD             	Liquid Liquid Extraction (LLE)
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	Amino acids and bioamines were analyzed with LC-MS/MS (MRM)
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Agilent 1290
CH:COLUMN_NAME                   	Zorbax Eclipse XDB-C18 (100 x 2mm)
CH:FLOW_GRADIENT                 	0% B for 0.5 min, 0% to 95% B for 5 min, hold at 95% B for 1 min, 95% to 0% B
CH:FLOW_GRADIENT                 	for 0.5 min, then hold at 0% B for 2.5 min
CH:FLOW_RATE                     	500 μL/min
CH:COLUMN_TEMPERATURE            	50
CH:SOLVENT_A                     	0.2% formic acid in H2O
CH:SOLVENT_B                     	0.2% formic acid in ACN
CH:INTERNAL_STANDARD             	13C5-glutamine, serotonine-d4, dopamine-d4, tryptophan-d5, serine-d3, and
CH:INTERNAL_STANDARD             	lysine-d8
CH:SAMPLE_INJECTION              	3 uL
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
AN:ACQUISITION_DATE              	2018 May
#MS
MS:INSTRUMENT_NAME               	ABI Sciex 5500 QTrap
MS:INSTRUMENT_TYPE               	Triple quadrupole
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	Amino acids and bioamines MRM mode Analyst 1.52
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	uL(plasma), pmole/mg (muscle)
MS_METABOLITE_DATA_START
Samples	NTB_1p	NTB_2p	NTB_3p	NTB_4p	NTB_5p	NTB_6p	TB_1p	TB_2p	TB_3p	TB_4p	TB_5p	TB_6p	5FU_1p	5FU_2p	5FU_3p	5FU_4p	5FU_5p	5FU_6p	BST100_1p	BST100_2p	BST100_3p	BST100_4p	BST100_5p	BST100_6p	BST200_1p	BST200_2p	BST200_3p	BST200_4p	BST200_5p	BST200_6p	NTB_1m	NTB_2m	NTB_3m	NTB_4m	NTB_5m	NTB_6m	TB_1m	TB_2m	TB_3m	TB_4m	TB_5m	TB_6m	5FU_1m	5FU_2m	5FU_3m	5FU_4m	5FU_5m	5FU_6m	BST100_1m	BST100_2m	BST100_3m	BST100_4m	BST100_5m	BST100_6m	BST200_1m	BST200_2m	BST200_3m	BST200_4m	BST200_5m	BST200_6m
Factors	Group:batch1 | Treatment:Control | Sample Source:plasma	Group:batch1 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch1 | Treatment:Control | Sample Source:plasma	Group:batch1 | Treatment:Control | Sample Source:plasma	Group:batch1 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch2 | Treatment:Control | Sample Source:plasma	Group:batch1 | Treatment:5FU | Sample Source:plasma	Group:batch1 | Treatment:5FU | Sample Source:plasma	Group:batch1 | Treatment:5FU | Sample Source:plasma	Group:batch2 | Treatment:5FU | Sample Source:plasma	Group:batch2 | Treatment:5FU | Sample Source:plasma	Group:batch2 | Treatment:5FU | Sample Source:plasma	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Group:batch1 | Treatment:BST204 | Sample Source:plasma	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Group:batch2 | Treatment:BST204 | Sample Source:plasma	Group:batch1 | Treatment:Control | Sample Source:muscle	Group:batch1 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch1 | Treatment:Control | Sample Source:muscle	Group:batch1 | Treatment:Control | Sample Source:muscle	Group:batch1 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch2 | Treatment:Control | Sample Source:muscle	Group:batch1 | Treatment:5FU | Sample Source:muscle	Group:batch1 | Treatment:5FU | Sample Source:muscle	Group:batch1 | Treatment:5FU | Sample Source:muscle	Group:batch2 | Treatment:5FU | Sample Source:muscle	Group:batch2 | Treatment:5FU | Sample Source:muscle	Group:batch2 | Treatment:5FU | Sample Source:muscle	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Group:batch1 | Treatment:BST204 | Sample Source:muscle	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Group:batch2 | Treatment:BST204 | Sample Source:muscle	Group:batch2 | Treatment:BST204 | Sample Source:muscle
L-Alanine	734	713	406	768	397	434	476	360	405	505	377	575	444	418	369	210	265	278	483	277	222	507	688	633	478	403	642	569	532	773	34.3	45.5	18.1	34.3	24	13.6	13.3	17	19.6	21.4	20.1	19.2	29.1	28.8	24.5	21.7	27	22.6	19.2	17.3	19.2	23.6	18.7	19.9	17.1	24.7	34.8	17.6	21.6	20.7
L-Arginine	24	31	29.4	24.6	29.2	30.6	49.1	42.4	38.6	50.4	33.5	44.5	43.5	41.5	31.2	41.9	19.6	24	30.8	19.1	25.3	24.7	45.3	31.9	20.6	27.85	44.7	29.3	21.6	39.9	2.9	3.4	0.6	0.9	0.9	0.7	2.3	1.8	1.9	1.5	1.6	1.9	1.6	1.1	2.1	1.7	1.8	1.3	1.4	2.5	2.5	1.4	1	1.2	2.9	1.8	2.6	2.4	1.7	1.5
D-Asparagine	113	102	77.2	75.5	99.7	64.3	101	88	72.2	84.9	68.1	100	107.5	158	106	108	95.1	71.5	90	80.7	50.2	53.7	59.7	65.2	70.4	72.9	70.55	72	91.9	77.2	3.4	5.7	1.5	2.9	2.8	1.3	2	2.1	1.5	1.7	1.7	1.5	4.5	4.4	2.9	3.2	3.6	3.1	2.8	1.3	2.1	3.5	2.5	1.6	3.4	3.1	3	3.1	2.8	1.5
L-Aspartic acid	7.76	9	6.01	7.37	8.14	6.87	17	17.7	17.8	16.4	21.5	15.8	12.55	17.9	11.9	19.8	10.7	19.1	11.9	4.86	6.39	10.2	16.9	17.3	9.35	12.75	13.7	11.6	15.8	13.1	4.4	5	1.1	3.2	4.1	2.2	2.2	2.1	1.8	1.8	2	1.9	3.4	1.9	3.6	3.1	3.4	2.6	3.2	1.9	2.3	2.7	3.1	2.6	4	3.2	2.4	4.6	3.3	2.3
L-Glutamine	337	360	323	319	346	436	410	447	363	418	457	413	418	372	357	336	394	356	352	285	350	322	474	313	338	508	552	288	472	404	59.3	52.3	43.9	85	53.4	48.9	48.8	50.8	40.3	48.2	46.2	46.8	77.2	68.4	39.3	31	68	66.5	37.1	35.1	38.7	38.9	29.9	49.7	61.4	109	55.8	46	55.4	88
Glycine	70.9	125	53.8	82.4	103	49.4	83.5	92.8	91.3	84	129	87.4	64.6	81.2	82.3	43.9	62.6	33.9	87.4	26.5	37.2	14.4	56.2	30.1	36.1	70.3	78.25	70.1	58	56.8	207	153.2	98.2	101	115.3	61.1	41.9	49.6	16.6	35.3	39.3	41.3	34.4	19.8	64.4	21.1	37.4	39	16.3	31.5	54	22.5	16.7	73.8	37.2	30.9	25.6	23.9	40	35.3
Histamine	0.0422	0.111	0.0484	0.0477	0.0586	0.0593	0.0604	0.0509	0.0538	0.0529	0.0625	0.0479	0.0788	0.0728	0.102	0.0861	0.0608	0.0878	0.0405	0.0301	0.0421	0.0338	0.0424	0.0211	0.0571	0.05115	0.0413	0.0294	0.0497	0.0789	0.2	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.2	0.2	0.4	0.2	0.4	0.3	0.3	0.2	0.2	0.4	0.3	0.4	0.3	0.3	0.4	0.3	0.4	0.4	0.3
L-Histidine	51.6	58.7	72.8	57	46.8	57.9	43.9	58	55.7	45.4	55.8	48.2	87.15	94.4	69	36.6	59.8	36.7	44.5	72.1	56.5	52.9	36	32.3	55.5	45.7	51.2	36.7	58.9	56.3	6.1	7.4	3.4	5.6	4.8	3.5	3.4	3.6	4.5	4.3	4.4	4.1	5.3	5.7	6.1	7.1	6.7	5.7	4.9	4.8	4.3	5.4	5.5	4.8	4.1	6.5	6.9	6.3	7.2	5.9
L-Isoleucine	437	540	490	419	422	467	490	414	505	452	414	525	455	368	584	384	430	465	563	578	419	291	572	314	378	347	355	313	349	449	1.7	2.3	1	2	2.3	1.7	1.1	1.2	1.2	1.4	1.5	2.2	3.4	2.8	2.2	3.5	4.2	3.8	1.3	0.8	1.5	2.7	2	1.1	2.4	2.2	1.5	2.2	2.4	1.3
L-Kynurenine	1.44	1.92	1.5	1.46	1.75	1.76	1.47	2.04	2.11	1.93	1.88	2.48	4.38	2.315	3.63	2.49	2.96	4.29	2.37	2.56	1.89	1.88	3.9	2.3	2.31	2.43	1.885	2.37	2.43	1.65	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
L-Leucine	1160	940	1160	1220	833	1180	905	801	963	920	1190	913	1190	791	1360	892	1420	1320	1130	1490	1030	580	1370	1010	719	677	986	765	641	909	3.6	4.8	2.9	3.9	4.9	3.3	2.5	2.5	2.7	2.7	3.4	3.8	7.9	5.8	5	7.7	9	8.5	3.2	1.7	3.5	5.5	4.9	2.5	6.4	5.4	3.1	5.2	5.5	3.9
L-Methionine	3590	4640	5500	3870	3230	4130	4680	2380	3770	3300	3900	4980	2680	2305	2680	2630	2210	2490	4230	3880	2080	2580	2210	3350	2750	2535	3440	3030	3160	2840	74.4	101.6	61.8	129.3	82.5	66.1	37.5	46.8	38.9	63.6	57.2	66.8	93.4	63.8	76.8	139.2	144.1	203.3	44.2	41.8	67.7	96.1	114.3	112.8	68.3	54.1	32.4	124.2	149.2	108
Methionine sulfoxide	1240	1430	897	564	786	935	1580	885	1240	730	1680	972	2930	1300	2380	2540	1170	2040	1570	1760	635	544	362	1190	1100	1161	976	650	1420	1390	17.1	30	20.5	17.6	26.4	13.4	16	15.8	14	15.8	18.7	30.4	72.8	36.6	58.8	50	49.3	75	16	14.5	19	29.6	24.8	40.3	22.7	12.2	10	24.6	46.3	26
L-Proline	12.8	12.4	7.43	17.5	17.2	9.57	16.3	10.4	14.2	16.7	21	18.8	21.1	14.4	14.8	15.4	8.56	12.5	22.3	17.5	5.16	9.86	24.2	17.4	10.4	17.4	19.7	14.3	11.5	18.9	7.7	5.9	4.6	5.8	4.1	4.1	2.8	4.2	2.1	3.9	4.1	4.2	5.9	4.6	6	4	8.7	9.3	2.4	4	5.5	2.1	3.9	3.9	7.1	3	4.3	4.3	4.4	7.6
L-Phenylalanine	193	165	177	148	124	164	171	142	147	150	119	192	162.5	297	239	182	169	224	208	92.8	153	81	203	121	159	129	129	152	109	166	0.8	0.9	0.8	0.9	1.1	0.7	0.6	0.8	0.7	0.6	0.7	1	1.6	1.3	1.4	2.1	2.1	2.1	0.8	0.6	0.7	1.2	1.1	0.7	1.1	1.1	0.8	1.3	1.4	1.3
L-Serine	87.2	113	96.2	67.8	79.2	54.7	71.6	67.9	68.5	65.5	62.9	61.5	106	84.8	87.4	109	47	49.1	106	74.7	59.9	67.3	52.6	69.8	74.9	81.4	116.45	73.2	62.8	63.7	5.9	9.5	7.8	10.6	6.4	5.8	4.2	5.1	4.3	4.4	5.4	5.2	4.7	5.2	8.4	6.3	7.7	6.5	4.1	4.2	7.3	7.6	7	5.8	5.1	4.7	6.8	9	8.4	6.7
4-Hydroxyproline	5.64	7.59	4.35	6.77	6.08	5.2	6.87	6.96	8.42	5.75	6.82	5.7	2.95	2.345	2.38	3.8	1.49	2.86	5.22	5.96	3.69	3.13	5.22	6.55	3.24	5.32	5.41	3.74	4.36	5.2	4	5.8	2.2	3.3	3	2.3	2.7	1.5	1.6	3	2.2	2.3	0.2	0.4	0.4	0.6	0.2	0.3	1.7	1.9	0.6	0.6	0.4	2.3	1.7	0.9	2.3	0.8	1.4	0.8
L-Threonine	150	150	103	141	123	133	104	111	114	122	149	145	196	186	185	131	142	116	160	149	54	84.2	102	113	120	108.75	132	117	127	156	13	16.5	6.5	10.2	7.8	5.3	6	5.7	6.6	5.3	6.4	5.2	10.1	9	9.6	9.9	10.4	9.4	7.7	8.9	7.2	9.3	7.2	6	9.5	7.5	9.6	8.9	9.3	8
Tryptophan	112	179	119	191	171	229	104	106	107	133	108	174	81.5	105.65	111	109	129	97.7	99.2	124	106	174	141	131	125	144	135.5	145	142	148	1.4	1.7	1.4	1.1	1.1	1.2	1.2	1.1	1.4	1.7	1.4	1.4	1.5	2	1.4	1.9	1.7	1.6	1.4	1.3	1.2	1.6	2.1	1.3	1.5	1.5	1.4	1.9	1.5	2
L-Tyrosine	32.6	32.1	41.2	30.6	34.4	25.6	15.7	13.2	21.1	21.2	13.3	17	19.95	30.2	27.8	19.1	10.5	9.16	17.6	16.7	10.1	7.92	9.75	15.6	12.2	15.35	11.6	12.9	13.4	14	4.6	5.4	1.5	3.4	2.5	1.6	1.3	1.2	1.6	1.2	1	1.6	2.6	1.8	2.2	2.5	2.3	2	1.4	1.4	1.7	1.4	1.9	1.9	1.9	2.1	2.2	2.2	1.9	1.3
L-Valine	3590	2870	3010	2430	2340	2860	2050	2680	2190	2680	2600	2260	3000	1980	2350	2350	2320	3210	3210	1600	2590	1480	3330	2440	1810	2380	2150	1570	2350	2330	10	12.1	8.4	12	12.9	8.9	5.1	7.4	5.6	6.8	7.9	13.3	18.2	12.1	12	17.2	20.9	26.2	7.1	4.2	8.4	13.4	10.5	6.8	11.2	7.9	8.4	11.7	14.2	11.9
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	KEGG ID	Pubchem ID
L-Alanine	C00041	5950
L-Arginine	C00062	6322
D-Asparagine	C01905	439600
L-Aspartic acid	C00049	5960
L-Glutamine	C00064	5961
Glycine	C00037	750
Histamine	C00388	774
L-Histidine	C00135	6274
L-Isoleucine	C00407	6306
L-Kynurenine	C00328	161166
L-Leucine	C00123	6106
L-Methionine	C00073	6137
Methionine sulfoxide	C02989	847
L-Proline	C00148	145742
L-Phenylalanine	C00079	6140
L-Serine	C00065	5951
4-Hydroxyproline	C01157	5810
L-Threonine	C00188	6288
Tryptophan	C00806	1148
L-Tyrosine	C00082	6057
L-Valine	C00183	6287
METABOLITES_END
#END